UPDATE: BTIG Starts BioAtla Inc. (BCAB) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 rises as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
UPDATE: Credit Suisse Starts BioAtla Inc. (BCAB) at Outperform
January 11, 2021 5:01 AM EST(Updated - January 11, 2021 6:23 AM EST)
Credit Suisse analyst Tiago Fauth initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Outperform rating and a price target of $49.00.
The analyst comments "The companys two lead proprietary programs targeting AXL (BA3011) and ROR2 (BA3021) are antibody-drug conjugates (ADC) designed with BCABs proprietary conditionally active biologics (CAB) technology. CAB molecules have... More
UPDATE: Jefferies Starts BioAtla Inc. (BCAB) at Buy Ahead of Two Separate Phase 2 Readouts
January 11, 2021 4:43 AM EST(Updated - January 11, 2021 8:52 AM EST)
Jefferies analyst Biren Amin initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Buy rating and a price target of $51.00 ahead of Ph2 interim readouts in H2' 21. Jefferies was joint book-running manager in BCAB's... More
JPMorgan Starts BioAtla Inc. (BCAB) at Overweight
January 11, 2021 4:42 AM ESTJPMorgan initiates coverage on BioAtla Inc. (NASDAQ: BCAB) with a Overweight rating and a price target of $45.00.
For an analyst ratings summary and ratings history on BioAtla Inc. click here. For more ratings news on BioAtla Inc. click here.
Shares of BioAtla Inc. closed at $38.25 yesterday.
... More